Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. [electronic resource]
Producer: 20140718Description: 1766-1771 p. digitalISSN:- 1879-0852
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Renal Cell -- drug therapy
- Disease-Free Survival
- Endpoint Determination
- Humans
- Indoles -- therapeutic use
- Interferon-alpha -- therapeutic use
- Kaplan-Meier Estimate
- Kidney Neoplasms -- drug therapy
- Multicenter Studies as Topic
- Pyrroles -- therapeutic use
- Randomized Controlled Trials as Topic
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Sunitinib
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.